GlassScriptPhysician profile
Farzad Alemi
NPI 1861525511
$47,961.75
in general payments reported to CMS, 2019-2025
24 companies · $5,268 in 2025
The $5,268 reported for 2025 was more than what 91% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2021: $3,198 · 2022: $13K · 2023: $14K · 2024: $13K · 2025: $5,268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Travel and Lodging: $8,465 · Honoraria: $3,000 · Food and Beverage: $1,299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,750.00 |
| Travel and Lodging | $8,464.81 |
| Honoraria | $3,000.00 |
| Food and Beverage | $1,298.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Applied Medical Resources Corporation | $45,568.23 | 2021-2025 | Epix Universal Clip Applier |
| Tela Bio, INC. | $1,016.37 | 2024-2025 | Ovitex 2s, Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Davol INC. | $498.71 | 2021-2023 | Phasix Mesh |
| Abbvie INC. | $306.61 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $56.69 | 2023-2025 | Tagrisso |
| Takeda Pharmaceuticals U.S.A., INC. | $55.04 | 2023 | Fruzaqla, Ninlaro |
| Incyte Corporation | $49.68 | 2021-2022 | |
| Coopersurgical, INC. | $42.75 | 2024 | Summit Doppler |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.09 | 2019 | |
| Gilead Sciences, INC. | $29.99 | 2023 | |
| Karyopharm Therapeutics INC. | $29.15 | 2023 | Xpovio |
| Novartis Pharmaceuticals Corporation | $28.28 | 2025 | |
| Jazz Pharmaceuticals INC. | $27.05 | 2024 | |
| Puma Biotechnology, INC. | $25.74 | 2024 | |
| Ethicon US, LLC | $24.96 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $23.12 | 2021 | |
| Stemline Therapeutics INC. | $22.99 | 2023 | Orserdu |
| Cti Biopharma Corp. | $21.81 | 2023 | Vonjo |
| Trevena, INC. | $19.27 | 2022 | |
| G1 Therapeutics, INC. | $18.83 | 2022 | |
| Glaxosmithkline, LLC. | $18.61 | 2021 | |
| Angiodynamics, INC. | $18.09 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.96 | 2023 | |
| Medtronic, INC. | $11.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farzad Alemi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.